Literature DB >> 26261257

Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival.

Hideki Ujiie1, Kyuichi Kadota1, Jamie E Chaft1, Daniel Buitrago1, Camelia S Sima1, Ming-Ching Lee1, James Huang1, William D Travis1, Nabil P Rizk1, Charles M Rudin1, David R Jones1, Prasad S Adusumilli2.   

Abstract

PURPOSE: To examine the significance of the proposed International Association for the Study of Lung Cancer, American Thoracic Society, and European Respiratory Society (IASLC/ATS/ERS) histologic subtypes of lung adenocarcinoma for patterns of recurrence and, among patients who recur following resection of stage I lung adenocarcinoma, for postrecurrence survival (PRS). PATIENTS AND METHODS: We reviewed patients with stage I lung adenocarcinoma who had undergone complete surgical resection from 1999 to 2009 (N = 1,120). Tumors were subtyped by using the IASLC/ATS/ERS classification. The effects of the dominant subtype on recurrence and, among patients who recurred, on PRS were investigated.
RESULTS: Of 1,120 patients identified, 188 had recurrent disease, 103 of whom died as a result of lung cancer. Among patients who recurred, 2-year PRS was 45%, and median PRS was 26.1 months. Compared with patients with nonsolid tumors, patients with solid predominant tumors had earlier (P = .007), more extrathoracic (P < .001), and more multisite (P = .011) recurrences. Multivariable analysis of primary tumor factors revealed that, among patients who recurred, solid predominant histologic pattern in the primary tumor (hazard ratio [HR], 1.76; P = .016), age older than 65 years (HR, 1.63; P = .01), and sublobar resection (HR, 1.6; P = .01) were significantly associated with worse PRS. Presence of extrathoracic metastasis (HR, 1.76; P = .013) and age older than 65 years at the time of recurrence (HR, 1.7; P = .014) were also significantly associated with worse PRS.
CONCLUSION: In patients with stage I primary lung adenocarcinoma, solid predominant subtype is an independent predictor of early recurrence and, among those patients who recur, of worse PRS. Our findings provide a rationale for investigating adjuvant therapy and identify novel therapeutic targets for patients with solid predominant lung adenocarcinoma.
© 2015 by American Society of Clinical Oncology.

Entities:  

Mesh:

Year:  2015        PMID: 26261257      PMCID: PMC4554749          DOI: 10.1200/JCO.2015.60.9818

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  37 in total

1.  Hazard function estimators: a simulation study.

Authors:  K R Hess; D M Serachitopol; B W Brown
Journal:  Stat Med       Date:  1999-11-30       Impact factor: 2.373

2.  Prognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis.

Authors:  Jung-Jyh Hung; Wen-Juei Jeng; Wen-Hu Hsu; Kou-Juey Wu; Teh-Ying Chou; Chih-Cheng Hsieh; Min-Hsiung Huang; Jung-Sen Liu; Yu-Chung Wu
Journal:  Thorax       Date:  2010-03       Impact factor: 9.139

3.  Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation.

Authors:  Kyuichi Kadota; Yi-Chen Yeh; Sandra P D'Angelo; Andre L Moreira; Deborah Kuk; Camelia S Sima; Gregory J Riely; Maria E Arcila; Mark G Kris; Valerie W Rusch; Prasad S Adusumilli; William D Travis
Journal:  Am J Surg Pathol       Date:  2014-08       Impact factor: 6.394

4.  Visceral pleural invasion does not affect recurrence or overall survival among patients with lung adenocarcinoma ≤ 2 cm: a proposal to reclassify T1 lung adenocarcinoma.

Authors:  Jun-Ichi Nitadori; Christos Colovos; Kyuichi Kadota; Camelia S Sima; Inderpal S Sarkaria; Nabil P Rizk; Valerie W Rusch; William D Travis; Prasad S Adusumilli
Journal:  Chest       Date:  2013-11       Impact factor: 9.410

5.  The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival.

Authors:  Arne Warth; Thomas Muley; Michael Meister; Albrecht Stenzinger; Michael Thomas; Peter Schirmacher; Philipp A Schnabel; Jan Budczies; Hans Hoffmann; Wilko Weichert
Journal:  J Clin Oncol       Date:  2012-03-05       Impact factor: 44.544

6.  Hazard rate estimation under random censoring with varying kernels and bandwidths.

Authors:  H G Müller; J L Wang
Journal:  Biometrics       Date:  1994-03       Impact factor: 2.571

7.  A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma.

Authors:  Kyuichi Kadota; Kei Suzuki; Stefan S Kachala; Emily C Zabor; Camelia S Sima; Andre L Moreira; Akihiko Yoshizawa; Gregory J Riely; Valerie W Rusch; Prasad S Adusumilli; William D Travis
Journal:  Mod Pathol       Date:  2012-04-13       Impact factor: 7.842

8.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

9.  Targeting of low-dose CT screening according to the risk of lung-cancer death.

Authors:  Anil K Chaturvedi; Hormuzd A Katki; Stephanie A Kovalchik; Martin Tammemagi; Christine D Berg; Neil E Caporaso; Tom L Riley; Mary Korch; Gerard A Silvestri
Journal:  N Engl J Med       Date:  2013-07-18       Impact factor: 91.245

10.  Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence.

Authors:  J-J Hung; W-H Hsu; C-C Hsieh; B-S Huang; M-H Huang; J-S Liu; Y-C Wu
Journal:  Thorax       Date:  2009-03       Impact factor: 9.139

View more
  64 in total

1.  Micropapillary and/or Solid Histologic Subtype Based on Pre-Treatment Biopsy Predicts Local Recurrence After Thermal Ablation of Lung Adenocarcinoma.

Authors:  Song Gao; Seth Stein; Elena N Petre; Waleed Shady; Jeremy C Durack; Carole Ridge; Prasad Adusumilli; Natasha Rekhtman; Stephen B Solomon; Etay Ziv
Journal:  Cardiovasc Intervent Radiol       Date:  2017-08-02       Impact factor: 2.740

2.  Is spread through alveolar spaces, the newly recognized pattern of invasion, a potential game changer in lung adenocarcinoma?

Authors:  Sarina Bains; Prasad S Adusumilli
Journal:  Ann Transl Med       Date:  2015-12

3.  Imaging Surveillance for Surgically Resected Stage I Non-Small Cell Lung Cancer: Is More Always Better?

Authors:  Melanie Subramanian; Jingxia Liu; Caprice Greenberg; Jessica Schumacher; George J Chang; Timothy L McMurry; Amanda B Francescatti; Tara R Semenkovich; Jessica L Hudson; Bryan F Meyers; Varun Puri; Benjamin D Kozower
Journal:  J Thorac Cardiovasc Surg       Date:  2018-10-24       Impact factor: 5.209

4.  Immunotherapy response modeling by ex-vivo organ culture for lung cancer.

Authors:  Iris Kamer; Elizabeta Bab-Dinitz; Oranit Zadok; Efrat Ofek; Teodor Gottfried; Inbal Daniel-Meshulam; Goni Hout-Siloni; Alon Ben Nun; Iris Barshack; Amir Onn; Jair Bar
Journal:  Cancer Immunol Immunother       Date:  2021-01-23       Impact factor: 6.968

Review 5.  Image-guided thoracic surgery in the hybrid operation room.

Authors:  Hideki Ujiie; Andrew Effat; Kazuhiro Yasufuku
Journal:  J Vis Surg       Date:  2017-10-28

6.  Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules.

Authors:  Giuseppe Pelosi; Alessio Pellegrinelli; Alessandra Fabbri; Elena Tamborini; Federica Perrone; Giulio Settanni; Adele Busico; Benedetta Picciani; Maria Adele Testi; Lucia Militti; Patrick Maisonneuve; Barbara Valeri; Angelica Sonzogni; Claudia Proto; Marina Garassino; Filippo De Braud; Ugo Pastorino
Journal:  Virchows Arch       Date:  2016-04-07       Impact factor: 4.064

7.  Competing risks analysis in the prognostic assessment of patients undergoing lung resection.

Authors:  Takashi Eguchi; Prasad S Adusumilli
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

8.  Visiting an old foe: distant recurrence following R0 lobectomy for pathological N0 lung adenocarcinoma.

Authors:  Sameer A Hirji; Thomas A D'Amico
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

9.  Stepwise Disease Progression Model of Subsolid Lung Adenocarcinoma with Cystic Airspaces.

Authors:  Woohyun Jung; Sukki Cho; Sungwon Yum; Jin-Haeng Chung; Kyung Won Lee; Kwhanmien Kim; Choon Taek Lee; Sanghoon Jheon
Journal:  Ann Surg Oncol       Date:  2020-05-03       Impact factor: 5.344

10.  Presence of micropapillary and solid patterns are associated with nodal upstaging and unfavorable prognosis among patient with cT1N0M0 lung adenocarcinoma: a large-scale analysis.

Authors:  Yonggang Yuan; Ge Ma; YaQi Zhang; Haiquan Chen
Journal:  J Cancer Res Clin Oncol       Date:  2018-02-01       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.